Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16124356 | 0.98 | CYP4F2 (0.38) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL13264348 | 0.98 | CYP4F2 (0.38) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL7937781 | 0.98 | CYP4F2 (0.38) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL91152 | 0.97 | SMN1; SMN2 (0.35) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL19480944 | 0.93 | CYP4F2 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL19480906 | 0.81 | FFAR1 (0.32) | — | |
| SCHEMBL13981494 | 0.80 | FDPS (0.37) | — | |
| SCHEMBL8297426 | 0.78 | — | — | |
| SCHEMBL15386615 | 0.78 | GGPS1 (0.40) | TSHR | |
| SCHEMBL16809409 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | disclosed |
| EP-2012799-B1 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| US-9157008-B2 | Anhydride copolymer top coats for orientation control of thin film block copolymers | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8163205-B2 | Durable transparent conductors on polymeric substrates | THE BOEING COMPANY (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-7994143-B2 | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates | CHIMERIX, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7749983-B2 | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates | CHIMERIX, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100038601-A1 | DURABLE TRANSPARENT CONDUCTORS ON POLYMERIC SUBSTRATES | THE BOEING COMPANY | 2010-02-18 | — | — | US | disclosed |
| EP-2154689-A2 | Durable transparent conductors on polymeric substrates | THE BOEING COMPANY (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CYP4F2 3826/4885CYP4A11 1495/4885SMN1; SMN2 1363/4885 |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CYP4F2 3826/4885CYP4A11 1495/4885SMN1; SMN2 1363/4885 |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | CYP4F2 2716/4885CYP4A11 2211/4885SMN1; SMN2 2004/4885 |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | CYP4F2 2716/4885CYP4A11 2211/4885SMN1; SMN2 2004/4885 |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CYP4F2 3826/4885CYP4A11 1495/4885SMN1; SMN2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.